GT201200257A - Composiciones sólidas - Google Patents

Composiciones sólidas

Info

Publication number
GT201200257A
GT201200257A GT201200257A GT201200257A GT201200257A GT 201200257 A GT201200257 A GT 201200257A GT 201200257 A GT201200257 A GT 201200257A GT 201200257 A GT201200257 A GT 201200257A GT 201200257 A GT201200257 A GT 201200257A
Authority
GT
Guatemala
Prior art keywords
solid compositions
hcv
hepatitis
treatment
methods
Prior art date
Application number
GT201200257A
Other languages
English (en)
Inventor
Bernd Liepold
Karin Rosenblatt
Peter Höelig
Rajeev Gokhale
Leena Prasad
Jonathan Miller
Eric A Schmitt
John B Morris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201200257A publication Critical patent/GT201200257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON COMPOSICIONES SÓLIDAS QUE COMPRENDEN COMPUESTOS ANTI-HCV Y CON MÉTODOS PARA USARLAS EN EL TRATAMIENTO DE INFECCIONES DEL VIRUS DE LA HEPATITIS C (HCV)
GT201200257A 2010-03-10 2012-09-10 Composiciones sólidas GT201200257A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10

Publications (1)

Publication Number Publication Date
GT201200257A true GT201200257A (es) 2014-09-26

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200257A GT201200257A (es) 2010-03-10 2012-09-10 Composiciones sólidas

Country Status (27)

Country Link
US (1) US20110312973A1 (es)
EP (1) EP2544689B1 (es)
JP (2) JP5717768B2 (es)
KR (1) KR101579079B1 (es)
CN (2) CN103118681B (es)
AR (1) AR081736A1 (es)
AU (1) AU2011224558B2 (es)
BR (1) BR112012022774A2 (es)
CA (1) CA2792601C (es)
CL (1) CL2012002500A1 (es)
CO (1) CO6640208A2 (es)
DO (1) DOP2012000245A (es)
EA (1) EA021570B1 (es)
EC (1) ECSP12012148A (es)
ES (1) ES2613608T3 (es)
GT (1) GT201200257A (es)
IL (1) IL221833A (es)
MX (1) MX2012010478A (es)
MY (1) MY156888A (es)
NZ (1) NZ602288A (es)
PE (1) PE20130198A1 (es)
SG (1) SG183985A1 (es)
TW (1) TWI490218B (es)
UA (1) UA104517C2 (es)
UY (1) UY33265A (es)
WO (1) WO2011112558A2 (es)
ZA (1) ZA201207093B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009387A1 (en) * 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
EP2658858A4 (en) * 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2847355A1 (en) * 2011-09-16 2013-03-21 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572355B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de aad para uso en el tratamiento del vhc
AU2015100283B4 (en) * 2011-10-21 2015-06-18 Abbvie Ireland Unlimited Company Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
US8853176B2 (en) * 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2866807A2 (en) 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6573550B2 (ja) * 2012-07-12 2019-09-11 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤の結晶形
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
PT2909205T (pt) 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
EP3016651A1 (en) 2013-07-02 2016-05-11 AbbVie Inc. Methods for treating hcv
TW201542581A (zh) 2013-09-11 2015-11-16 Univ Emory 核苷酸與核苷治療組成物及其相關用途
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2015084953A1 (en) 2013-12-04 2015-06-11 Abbvie Inc. Crystal forms
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015116594A1 (en) 2014-01-28 2015-08-06 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
KR102379639B1 (ko) * 2014-06-18 2022-03-28 에프. 호프만-라 로슈 아게 비이온성 계면활성제를 포함하는 약학 조성물
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017037593A2 (zh) * 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina
EP3595638A4 (en) * 2017-03-15 2020-09-16 Cerecin Inc. MEDIUM CHAIN TRIGLYCERIDE PHARMACEUTICAL COMPOSITIONS HIGH ACTIVE INGREDIENT AND PROCESS RELATED THEREOF
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
IL283450B1 (en) * 2018-11-30 2024-02-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
RS20050741A (en) * 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for hepatitis c viral protease inhibitors
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
AR054122A1 (es) * 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
TWI383980B (zh) * 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
KR101629523B1 (ko) * 2007-12-21 2016-06-10 에프. 호프만-라 로슈 아게 대환 화합물의 제조방법
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
AR072991A1 (es) * 2008-08-07 2010-10-06 Schering Corp Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
EP2544689A4 (en) 2014-04-02
JP2015145387A (ja) 2015-08-13
KR101579079B1 (ko) 2015-12-21
CN103118681A (zh) 2013-05-22
CA2792601C (en) 2015-09-29
TW201202239A (en) 2012-01-16
NZ602288A (en) 2014-02-28
ES2613608T3 (es) 2017-05-24
AR081736A1 (es) 2012-10-17
AU2011224558B2 (en) 2014-02-27
IL221833A (en) 2017-01-31
WO2011112558A3 (en) 2012-01-05
ECSP12012148A (es) 2012-10-30
ZA201207093B (en) 2013-05-29
UY33265A (es) 2011-10-31
EP2544689A2 (en) 2013-01-16
AU2011224558A1 (en) 2012-09-27
BR112012022774A2 (pt) 2017-09-12
CO6640208A2 (es) 2013-03-22
PE20130198A1 (es) 2013-03-24
WO2011112558A2 (en) 2011-09-15
TWI490218B (zh) 2015-07-01
JP5890553B2 (ja) 2016-03-22
CN104771364B (zh) 2018-05-25
SG183985A1 (en) 2012-10-30
JP5717768B2 (ja) 2015-05-13
MY156888A (en) 2016-04-15
MX2012010478A (es) 2013-02-01
CA2792601A1 (en) 2011-09-15
KR20130048210A (ko) 2013-05-09
JP2013522208A (ja) 2013-06-13
US20110312973A1 (en) 2011-12-22
CN104771364A (zh) 2015-07-15
EP2544689B1 (en) 2017-01-11
DOP2012000245A (es) 2013-02-15
CL2012002500A1 (es) 2012-12-07
EA201290892A1 (ru) 2013-03-29
CN103118681B (zh) 2015-02-18
UA104517C2 (uk) 2014-02-10
EA021570B1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
GT201200257A (es) Composiciones sólidas
GT201300093A (es) Compuestos antivirales
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
CO6700883A2 (es) Inhibidores del virus de la hepatitis c
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
CL2015002445A1 (es) Compuestos amida para el tratamiento del vih
HN2009000792A (es) Inhibidores de la proteasa ns3 del hcv
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
ECSP14013312A (es) Composiciones para el tratamiento de vhc
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
GT201100056BA (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c (segunda solicitud fraccionaria de la solicitud de patentes de invención no. a-2011-00056).
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
SV2006002347A (es) Compuestos de piridazinona
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
IN2014CN03113A (es)
EA201390155A1 (ru) Комбинации ингибиторов вируса гепатита с
UY34066A (es) Inhibidores del virus de la hepatitis c
CR20110505A (es) Compuestos organicos y sus usos
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
IN2014CN00572A (es)